Adaptive Pharmacogenomics, LLC

Pharmacogenomics. 2010 Apr;11(4):469-70

Authors: Gurwitz D, Pirmohamed M

Lack of knowledge regarding genotype-phenotype correlations is often cited as the major barrier delaying the uptake of pharmacogenomics into routine medical practice.

Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.

Pharmacogenet Genomics.

Eur J Clin Pharmacol.

Researchers have discovered a genetic biomarker with a significant association to kidney failure. Researchers have also initiated an investigation into the ways that the PVT1 gene impacts development of diabetic kidney disease.

Comb Chem High Throughput Screen. 2010 Feb;13(2):145-58

Authors: Foti RS, Wienkers LC, Wahlstrom JL

Advances in drug interaction screening have resulted in reduced compound attrition rates due to unfavorable CYP-mediated drug interactions in clinical trials and improved patient safety.

Minerva Pediatr. 2009 Dec;61(6):615-7

Authors: Iolascon A, Russo R, Capasso M

PMID: 19935509 [PubMed - indexed for MEDLINE]

Ig Sanita Pubbl. 2010 Jan-Feb;66(1):115-32

Authors: Sgambato A, Ripani M, Spica VR

The development of genetic epidemiology in oncology has made possible more frequent analysis of high risk groups, allowing the development of promising susceptibility indicators. The main public health implications include screening and new perspectives for pharmacogenetics and nutrigenomics.

MORRISVILLE, N.C., June 21 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in applied clinical pharmacogenomics, announced today that Rick Williams has joined the organization as Chief Executive Officer and a member of the Boar...

Biochem Biophys Res Commun. 2010 May 21;396(1):90-4

Authors: Ingelman-Sundberg M, Sim SC

Important interindividual differences in drug pharmacokinetics cause absence of drug response or adverse drug reactions in significant fractions of the populations.

Pharmacogenet Genomics.